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The Plasmodium parasite undergoes dramatic morphological and metabolic 
transformations as it adapts to diverse environments within a  mosquito vector and a 
vertebrate host. During liver infection, the morphological changes of sporozoites (insect 
forms) includes the elimination of micronemes, organelles previously required for 
hepatocyte penetration. Preliminary experimental evidence suggests that Plasmodium 
utilizes an autophagic pathway that shares components with the unconventional protein 
secretion (UPS) pathway for microneme clearance from liver forms. The UPS pathway is 
implicated in the sequestration and expulsion of damaged proteins or organelles, bypassing 
the endoplasmic reticulum, instead requiring ATG8, and the Golgi reassembly and stacking 
protein (GRASP), a process called exophagy. In exophagy, GRASP has been identified as 
a molecular effector, tethering autophagic vesicles to the cell plasma membrane for cargo 
release. A GRASP ortholog is present in Plasmodium but its physiological role remains 
elusive. To investigate the relevance of Plasmodium GRASP to malaria infection, we have 
engineered a knockout Plasmodium mutant, named PbGRASP-KO (Plasmodium berghei 
GRASP Knockout). The objective of this study is to explore the role of P. berghei GRASP 
through all stages of the parasite’s lifecycle, and particularly the possible involvement of 
GRASP in exophagy of micronemes during liver stage development. If PbGRASP-KO 
parasites are unable to clear micronemes during the transformation of sporozoites to liver 
stage trophozoites, this will subsequently impact parasite multiplication in the liver. 
Comparing the development of P. berghei WT and PbGRASP-KO in the mosquito, liver, 
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and blood stages, we show that PbGRASP-KO displays no growth defects in the mosquito 
and blood stages. However, after sporozoite inoculation of the PbGRASP-KO into mice, a 
spike in blood stage parasitemia was observed for several days. Interestingly, 
morphological examination of blood stage parasites after sporozoite inoculation shows a 
greater number of ring stage parasites than WT. Through fluorescence and electron 
microscopy of infected hepatocytes, we observe that the PbGRASP-KO was able to clear 
micronemes effectively, despite a more pronounced accumulation of micronemes beneath 
the parasite plasma membrane, and PbGRASP-KO underwent normal schizogony. We 
conclude that GRASP may have a role outside of the liver stage, perhaps during initial 
blood stage development. 
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Introduction 
Epidemiology and current options against malaria 
Malaria is a globally prevalent, immensely debilitating disease. With half of the 
planet’s population living in endemic countries, the public health significance of malaria 
cannot be understated (1). The causative agent, the apicomplexan Plasmodium spp., is 
transmitted through the bite of an infected elusive insect and is responsible for a reported 
219 million malaria cases each year, and ~450,000 deaths (1). Although the morbidity and 
mortality of malaria are staggering, the case number has decreased from 239 million cases 
reported in 2010 (1). Progress is largely due to the immense effort by the global health 
community to reduce malaria mortality and morbidity through the improvement of vector 
control and the distribution of antimalarial drugs (1). With ~20 million fewer malaria cases 
in ten years, progress towards eliminating malaria is reasonably optimistic from a clinical 
and economic standpoint (1). However, it is important to recognize that previous progress 
in the reduction of malaria has stalled, with morbidity increasing by an estimated 2 million 
cases in 2018 compared to 2016 (1). In endemic countries, the burden of disease most 
heavily falls on pregnant women and children under the age of five, children under five 
represented 61% of all malaria deaths in 2017 (1). The increased risk of malaria infection 
in children is due to a loss of maternal antibodies and a lack of specific immunity to the 
Plasmodium antigens (2).  
Antimalarial drugs have had a significant impact on the reduction of global malaria 
deaths. Artemisinin combination therapies (ACTs) are considered the gold standard of 
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antimalarial drugs due to drug potency, targeting all stages of the blood stage parasite (3). 
The WHO recommends ACTs as the first line treatment for all global malaria cases; 
however, Plasmodium falciparum, the species of Plasmodium causing greatest disease 
burden and mortality in humans, has historically been the primary target (3). The success 
of ACTs has led to broad use, and unfortunately, resistant populations of P. falciparum in 
South East Asia have already emerged (3, 4).  
Vaccines are an ideal public health asset, as they strengthen the immune system to 
combat an infection prior to clinical manifestation of disease symptoms through the 
establishment of immune memory. Currently, the RTS, S /AS01 vaccine is the only 
licensed malaria vaccine for human use (5). RTS, S is a recombinant protein-based malaria 
vaccine that contains antigenic peptides derived from the circumsporozoite protein (CSP) 
of P. falciparum, mixed with a liposome adjuvant (6). Targeting CSP can block the 
sporozoite form of the parasite from invading a hepatocyte, preventing the progression of 
the parasite’s lifecycle into the blood, and stopping clinical symptoms of malaria before 
their manifestation. However, the RTS, S/AS01 vaccination regimen has shown to not 
protect the entire at-risk age group, such as children 1 to 3 months, and the rate of vaccine 
efficacy diminishes over time (6). During a phase 3 trial throughout seven sub-Saharan 
African countries, vaccine efficacy wanes from 27 to 18.3% in children 6-12 weeks of age, 
over a 48-month period (6). Children ages 5-17 months see vaccine efficacy wane from 
45.1 to 28.3% over a 48-month period (6).  
Emerging resistance to ACTs and limited success observed in current vaccine trials 
jeopardizes progress towards reducing malaria mortality and highlights the importance for 
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continued research on the biology of Plasmodium, in hopes of finding new drug targets and 
protective antigens.  
The biology of the malaria parasite 
In addition to P. falciparum, human malaria is caused by four other Plasmodium species 
including P. malariae, P. vivax, P. ovale, and P. knowelsi. Illustrated in Figure 1, the Plasmodium 
life cycle begins when an infected female Anopheles spp. mosquito takes a blood meal, passing the 
infectious sporozoite from the salivary duct to a human host. The slender sporozoite is motile, and 
invasion-competent, possessing a cytoskeleton composed of microtubules, and an inner membrane 
complex (IMC), an organelle forming a double membrane layer beneath the parasite’s plasma 
membrane, to maintain the pointed, elongated shape of the sporozoite until a hepatocyte can be 
located and penetrated (7, 8). 
Once deposited in the host dermis, Plasmodium utilizes CSP that uniformly 
decorate the sporozoite surface for gliding motility, entering the bloodstream as the 
pathway to the liver (9). Once the sporozoite localizes to the host liver, CSP facilitates 
attachment to a hepatocyte, and the parasite can invade (9). The hepatocyte is an important 
cellular environment for the Plasmodium parasite, where it undergoes necessary replication 
prior to the clinically relevant blood-stage infection. Attachment and invasion are 
additionally facilitated through proteins discharged from microneme and rhoptry 
Plasmodium organelles in the sporozoite (10). Upon invasion, the parasite develops a 
parasitophorous vacuole (PV) derived initially from the cellular membrane of the host cell 
and then from material present in the rhoptry organelles (11). The PV is an important niche 
for the intracellular parasite, protecting it during replication through the evasion of host 
immune factors (12, 13). The unique membrane composition of the PV precludes fusion 
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with host destructive organelles such as lysosomes. The PV of Plasmodium liver forms is 
permeable to host cell solutes, allowing the Plasmodium parasite to acquire nutrients from 
its host (14). Following hepatocyte invasion, micronemes are expelled into the PV as they 
contain superfluous proteins that need to be purged from the sporozoite as it transforms 
into a replicative liver form (10). Inside the hepatocyte, the sporozoite begins to undergo 
dramatic morphological changes as it transitions from the slender infectious sporozoite to 
a round, metabolically active trophozoite, the first liver stage (7, 15). The cytoskeleton and 
IMC are dismantled and expelled into the PV space (16). Schizogony, a rapid replicative 
process of nuclear divisions, transforms the trophozoite into an exoerythrocytic schizont 
(17). As the parasite grows during the process of schizogony, it manipulates and stretches 
the hepatocyte, while generating new organelles for the developing asexually produced 
progeny (17). At the end of schizogony, merosomes packed with hepatic merozoites are 
surrounded by host plasma membrane and eventually burst the host hepatocyte (18). 
Merosomes, like individual coin purses filled with loose change, release thousands of 
mononucleated merozoites into the bloodstream of the host. Hepatic merozoites are 
invasion competent for red blood cells (RBC), transforming through erythrocytic forms of 
trophozoites and schizonts. The erythrocytic schizonts lyse host RBCs and release 
mononucleated erythrocytic merozoites into the blood, continuing the blood-stage cycle of 
Plasmodium (19). This cyclical pattern of invasion, replication, and egress in the blood 
stage is the pathological driver of the classical malaria disease symptoms (20). Antigens 
and parasite waste proteins released into the blood during RBC lysis induce cyclical bouts 
of fever and anemia (21). A subset of erythrocytic merozoites develops into a unique blood-
stage form of sexual gametocytes, infectious to a female mosquito (21). When sexual 
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gametocytes are ingested by female mosquitoes during a blood meal, they mature into 
female and male gametes that fuse within the mosquito midgut, forming a fertilized zygote 
called an ookinete (22). The ookinete is motile and can traverse the mosquito midgut wall, 
developing into an oocyst (21, 22). Sporozoites form within the oocyst through asexual 
replication. After rupturing the oocyst, sporozoites migrate to the salivary glands of the 
mosquito host, where they wait for the mosquito’s next blood meal to enter their next host 
to complete the cycle (21, 22). 
Autophagy and Plasmodium metamorphosis 
The Plasmodium life cycle involves multiple dramatic phenotypic transformations 
as it cycles through unique tissues of an insect and vertebrate host. For example, in a human 
host, Plasmodium must transform from the long and slender, invasion ready sporozoite to 
the rounded metabolically active, and replication-competent trophozoite in the hepatocyte 
(15). Organelles that are required for invasion and maintaining the sporozoite structure, 
such as the cytoskeleton, rhoptry, micronemes, and IMC, are no longer useful, and are 
eliminated from the parasite. During differentiation, many organisms discard organelles by 
autophagy (23, 24). Autophagy is a biological process utilized by eukaryotic cells to 
maintain homeostasis (23). This process can be utilized to eliminate redundant, senescent, 
damaged proteins or organelles, provide nutrients to the cell, or degrade intracellular 
pathogens, colloquially referred to as “housekeeping” activities (24).  
In eukaryotic cells, conventional protein secretion (CPS) is considered the 
“standard” method for the trafficking of proteins. In the CPS pathway, cargo proteins are 
recognized through a transmembrane domain signal peptide and trafficked from the 
endoplasmic reticulum (ER) for protein folding and maturation, to the Golgi organelle, 
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where proteins are further processed and packaged into secretory vesicles (25). Processed 
proteins are then trafficked to a final destination (25). Unconventional protein secretion 
(UPS), less commonly described, is a pathway for the secretion of proteins lacking a signal 
peptide, thus bypassing the secretory pathway, and requiring autophagy machinery (25). In 
eukaryotic cells, the UPS is generally observed as a response to cellular stress, such as 
starvation or mechanical stressors (25). In the UPS, proteins are engulfed into an 
autophagosome that fuses with multivesicular bodies (MVB) to form amphisomes that then 
fuse with the plasma membrane to release the cargo. An UPS-like pathway can be also 
involved in the release of damaged proteins or organelles into the environment, named 
secretory autophagy or exophagy. In canonical (macro)autophagy, cargo is sequestered by 
a double sac membrane, that expands, developing into a closed autophagosome that fuse 
with lysosomes forming autolysosomes for degradation (26). Exophagy also involves the 
selective cytoplasmic enclosure of large cargo or organelles in autophagosomes, which 
fuse with MVB to form an amphisome, which can then be tethered to the cell plasma 
membrane, dumping cargo outside of the cell (10, 24, 25, 26, 27).  
Autophagy Related Gene (ATG) proteins are responsible for the function and 
regulation of the UPS pathway (28). Through the sequencing of Saccharomyces cerevisiae, 
a yeast model with a characterized UPS pathway, and an in silico comparative analysis to 
the P. falciparum genome, ~15 orthologs of ATG proteins found in S. cerevisiae are also 
identified in P. falciparum. This indicates that the Plasmodium parasite has a rudimentary 
set of autophagy genes. Transcriptomic analysis suggests the autophagy orthologs found 
in P. falciparum have a role in induction and selection of cargo, the formation of a 
phagophore, assembly of the autophagosome from the phagophore, and degradation of the 
 7 
autophagic body membrane (26, 29). Under drug stress, the formation of organellar 
structures in the cytoplasm that  are analogous to autophagosomes, has been observed in 
the erythrocytic forms of Plasmodium prior to cell death, further confirming Plasmodium 
does possess and use the machinery for macroautophagy (30). Individual genes that consist 
of an ubiquitin-like ATG8 conjugation system facilitate the formation of the 
autophagosome and are all present in the Plasmodium genome (10). Plasmodium ATG8 
proteins, structurally similar to ATG8 orthologs found in yeast, have been observed 
localizing to the apicoplast (an endosymbiotic plastid organelle), a potential spot for the 
derivation of proteins for the formation of the phagophore (15). 
 As previously mentioned, micronemes are eliminated from sporozoites during 
conversion into trophozoites (7). ATG8 structures have been observed colocalizing with 
micronemes identifiable by immunostaining of the microneme protein, thrombospondin-
related anonymous protein (TRAP). In Figure 2, at 1-h post-invasion, TRAP is uniformly 
dispersed across a GFP-expressing Plasmodium berghei parasite. By 4-h post-infection 
(p.i.), the P. berghei parasite has begun to bulge in the center, the distal ends of the 
sporozoite pulling inward as it transforms into a rounded trophozoite. By 10-h p.i., the 
parasite has rounded fully, and the TRAP staining is found in distinct puncta as they are 
prepared to be expelled into the PV. At 24-h p.i., the Plasmodium TRAP are found within 
the PV, where they may be degraded (7). Importantly, lysosomal organelles have not been 
identified in the hepatic form of the Plasmodium parasite (10). The autophagosomes that 
contain micronemes to be eliminated, likely fuse with the parasite plasma membrane (10). 
Similar to the UPS for protein secretion, it remains possible that autophagosomes fuse with 
MVBs and the formed amphisomes fuse with the parasite plasma membrane in 
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Plasmodium liver forms for microneme evacuation, as depicted in the hypothetical model 
in Figure 3.  
The importance of a secretory autophagy pathway to Plasmodium development is 
incentive for continued research into the biological pathways that mediate the 
transformation and survival of this complex parasite. 
GRASP 
In the mammalian cell, the Golgi complex plays a central role in secretion through 
the processing and packaging of macromolecules that, like proteins, are synthesized by the 
cell (31). With three functional distinct domains consisting of the cis, medial, and trans, 
the Golgi complex is engaged in the CPS pathway, which leads to the secretion of cellular 
cargo outside of the plasma membrane or the internal degradation of cargo through fusion 
with lysosomes (32, 33). Peripheral proteins called Golgi reassembly and stacking proteins 
(GRASP), are ubiquitous across all eukaryotic cells and engage the Golgi organelle at the 
surface membrane (33). Mammals possess two GRASP genes, referred to as GRASP55 
and GRASP65 (32, 34, 35, 36). A conserved myristoylation motif is located at the N-
terminus of GRASP55 and GRASP65 and has been identified as the binding motif that 
facilitates specific protein–protein interactions, and the association of GRASP proteins to 
cellular membranes (37). The tethering nature of GRASP is responsible for the formation 
of the stacked cisternae structure of the mammalian Golgi organelle, as depicted in Figure 
4 (38, 35).  
As a tethering protein, GRASP has also been characterized in the eukaryotic cell’s 
UPS pathway during periods of cellular stress (32). Acyl-CoA binding protein (ACBP) has 
been studied as a model for the unconventional protein secretion pathway in Dictyostelium 
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discoideum (13, 39). ACBP secretion is necessary for the differentiation of spores but lacks 
a signal peptide, preventing engagement in the CPS pathway. Through gene deletion 
assays, ACBP secretion has shown to be entirely dependent on GRASP and 
autophagosome machinery, including ATG8/LC3, for autophagosome formation and 
amphisome secretion from the cell membrane (13, 39). GRASP is observed localizing to 
the cell plasma membrane, possibly facilitating the tethering of amphisomes to the cell 
plasma membrane (13). In mutant D. discoideum lines with the GRASP gene knocked out, 
amphisomes containing ACBP do not leave the cell membrane, and congregate near the 
cell membrane surface (13, 39).  
UPS in eukaryotic cells could provide insight into GRASPs role in the Plasmodium 
secretory autophagy pathway. Unlike the related apicomplexan Toxoplasma gondii, which 
possesses a stacked Golgi organelle anterior to the nucleus of the parasite, Plasmodium 
parasites lack a defined stacked Golgi organelle (40). The Plasmodium Golgi organelle is 
dispersed through the cytosol of the parasite and is comprised of unstacked cis and trans-
cisternae (41). The structure of the Plasmodium Golgi could suggest that GRASP does not 
have a role in the tethering of Golgi cisternae. However, Plasmodium does have an ortholog 
of a GRASP gene. Additionally, analysis of P. falciparum in the asexual blood stage shows 
PfGRASP also possesses an N-terminal myristoylation motif (42). Could this suggest that 
the function of the Plasmodium GRASP gene is specific to UPS? If so, GRASP could be 
of critical importance in Plasmodium autophagy for the elimination of micronemes, a 
process that has already been emphasized as highly important for parasite transformation 
and survival. 
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As shown in Figure 5, reverse transcriptase-polymerase chain reaction (RT-PCR) 
has detected the level of GRASP expression in the liver over time at 1, 2, and 3 days p.i., 
with P. berghei (10). PbGRASP is expressed throughout the liver stage development of the 
parasite, further supporting the hypothesis that there is a potential role for GRASP in the 
transformation that occurs from invasion to late liver stage.  
Aim 
The objective of this study is to explore the role of GRASP in P. berghei through 









Materials and Methods 
Reagents and antibodies 
 All chemicals were obtained from Sigma (St. Louis, MO) or Thermo Fisher 
Scientific (Waltham, MA) unless otherwise stated. Antibodies used for the 
immunofluorescence assays included: Mouse anti-CSP (3D11) and mouse anti-HSP70 
(4C9) (diluted at 1:100), a generous gift from Prof. Fidel Zavala (Johns Hopkins 
University) and rabbit anti-TRAP (diluted at 1:100) kindly provided by Prof. Photini Sinnis 
(Johns Hopkins University), and rat anti-ATG8 (diluted at 1:300) (7). All DAPI staining 
was performed at a dilution of 1:1000 with a concentration of 1 µg/ml. Secondary 
antibodies used for immunofluorescence assays included: anti-mouse (Alexa-488), anti-
mouse (Alexa-555), anti-rabbit (Alexa-647), and anti-rat (Alexa-488). 
Mammalian cell lines, bacterial cells and parasite strains 
The commercial mammalian cell line used in this study is mouse Hepa1-6 (ATCC, 
CRL-1830). The transformed E. coli cells are One Shot® TOP10 Chemically 
Competent E. coli (Thermo Fisher, USA). The Hepa1-6 cell line was chosen for its 
monolayer growth pattern and grown in cell medium consisting of αMinimum essential 
medium (αMEM) with 10% Fetal Bovine Serum (FBS), 2 mM of L-Glutamine, 100 U/ml 
of Penicillin-Streptomycin, and 0.25 μg/ml Fungizone at 37°C in an atmosphere of 5% 
CO2. One Shot® TOP10 Chemically Competent E. coli were grown, after transformation 
with appropriate plasmid, in LB medium containing 100 μg of ampicillin.  P. berghei 
 12 
ANKA was selected as the background strain for our study due to the use of the previously 
generated mutant ATG8 Over Expressor (PbATG8-OE). Generation of an ATG8-OE and 
PbGRASP-KO under the same strain can be used to generate information regarding the 
relationship between PbGRASP and ATG8 in the Plasmodium secretory autophagy 
pathway. 
In vivo malaria model  
All procedures were conducted under the following permits issued to the Johns 
Hopkins University School of Public Health Institutional Animal Care and Use Committee 
protocol #MO19H482. Swiss Webster female mice were the chosen rodent model for all 
experiments. A grouping of 5 mice for each infection type was maintained across all 
experiments. All mouse dissections were performed under anesthesia, mice receiving 200 
μL of ketamine per mouse (ketamine 100 mg/ml, and prochlorperazine (Acepromazine) 10 
mg/ml in 0.9% saline). 
Plasmodium sporozoite cultivation 
Salivary glands were dissected from infected female Anopheles stephensi 
mosquitoes between 21 and 26 days p.i. and stored on ice in 1X Phosphate Buffered Saline 
(PBS). A 27.5-gauge needle was used to disrupt the salivary glands and release P. berghei 
sporozoites, before dilution in 1X PBS for in vivo infection. For infection of Hepa1-6 cells, 
dissected salivary glands were stored in αMEM with 100 U/ml of Penicillin-Streptomycin 
(PS), and 0.25 μg/ml of Fungizone. Sporozoites were further diluted in 2% FBS in 1X PBS 
before counting using a C-Chip hemocytometer.  
 13 
Cloning 
To assess the role of PbGRASP in the development of the Plasmodium parasite, a 
GRASP knockout (PbGRASP-KO) mutant was generated by Dr. Tejram Sahu at Johns 
Hopkins University. The cloning plasmid, pDEF, a generous gift from Prof. Sean Prigge 
(Johns Hopkins University), was used as it has the selection marker, human dihydrofolate 
reductase (hDHFR), that helps with the selection of transformed clones. 
A selection of a 1259 base pair (bp) region downstream of the PbGRASP gene and 
an 889 bp region upstream of the PbGRASP gene represent the respective 3’ and 5’ 
untranslated regions (UTRs) that flank our gene of interest. The UTRs were amplified from 
P. berghei genomic DNA (gDNA) using EXPAND TM High Fidelity polymerase.  
A forward and reverse primer (primers 1, 2) were designed to specifically amplify 
the 5’ UTR from P. berghei gDNA. Forward and reverse primers for the 3’UTR were also 
designed (primers 3, 4) (Chart 1). Each primer sequence contains restriction enzyme cut 
sites used for future digestion steps. Each 50 μl reaction is a composition of two master 
mixes; mix 1: deoxynucleotide mix (10 mM), forward primer 300 nM, reverse primer 300 
nM, template DNA 200 ng, sterile double distilled water up to a total volume of 25 μL; 
mix 2: ExpandTM High Fidelity enzyme 0.75 μL, ExpandTM High Fidelity Buffer (10x) 
with 15 mM MgCl2, sterile double-distilled water to a total volume of 25 μL. Polymerase 
chain reaction (PCR) was performed under the following thermocycler conditions: initial 
denaturation of 94°C for 5 minutes, followed by 5 cycles of 94°C for 30 seconds, 60°C for 
30 seconds, 72°C for 1.5 minutes, 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 
and 72°C for 1.5 minutes with an additional 5 seconds/cycle extension time for each cycle. 
A final extension cycle of 72°C was performed for 7 minutes and samples were stored at 
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4°C. PCR products were analyzed for their size by electrophoresis on a 1% agarose gel 
stained with ethidium bromide and imaged using UV light.  
The amplified 5’ UTR gDNA and the pDEF vector DNA were digested with 
HindIII and PstI restriction enzymes, cutting at the specific cut sites amplified by primers 
1 and 2 (Chart 1). The cloning vector and 5’UTR restriction digestion occurred under the 
following conditions: 37°C for 60 minutes followed by a heat inactivation step of 80°C for 
20 minutes.  
The ThermoFisherTM Rapid DNA Ligation Kit was used to ligate the digested 
5’UTR into the digested vector, at a 1:3 molar ratio of vector DNA (ng) concentration to 
insert DNA (ng) concentration. Four microliters of Rapid DNA Ligation buffer, 1 μL of 
ligase, and sterile double distilled water to a total volume of 20 μL was added to the vector-
insert ratio. The ligation reaction proceeded at 22°C for 30 minutes, remaining at 4°C until 
transformation. 
To clone the 3’ UTR into the pDEF vector, the amplified 3’UTR and pDEF vector, 
now containing the 5’UTR, were digested with EcoRI and KpnI restriction enzymes, 
cutting at the sites amplified by primers 3 and 4 (Chart 1). The pDEF vector and 3’ insert 
was incubated in a thermocycler at 37°C for 60 minutes followed by a heat inactivation 
step of 65°C for 20 minutes. The same ligation protocol was followed for the ligation of 
the 3’UTR into the pDEF vector that was completed for cloning of the 5’UTR, accounting 
for changes in vector and insert DNA concentration.  
Transformation 
Ten microliters of the recombinant plasmid were added to One-Shot TOP10 E. coli 
cells and placed on ice for 30 minutes. The cells were subjected to heat-shock at 42°C for 
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30 seconds and placed in ice water for 5 minutes. Next, 250 μL of SOC outgrowth media 
was added to the cells and incubated for 1 hour at 37oC with continuous shaking at 220 
rpm. The transformed E. coli cells (~80 µl) were plated on LB. agarose plates with 100 μg 
of Ampicillin. Plates were incubated for 16 hours (h) at 37°C. Multiple colonies were 
screened by plasmid minipreps and restriction digestion using appropriate restriction 
enzymes. Restriction positive clones were sequenced to confirm presence of both the 5’ 
and 3’ UTRs. Successfully transformed E. coli clones were preserved with a 1:1 ratio of 
40% glycerol and bacterial cell culture and stored at -80°C. 
Transfection 
To transfect P. berghei (ANKA), naïve mice were interperitoneally infected with 
blood stage WT P. berghei parasites. Parasite infected blood was extracted through a 
terminal cardiac puncture at ~4% parasitemia, and further cultured for 22-h at 5% CO2 and 
37°C in 1640 RPMI parasite culture media that consists of 6 mL of Fetal Bovine Serum 
(FBS) to 1 mL of blood, 750 μL of HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), and 300 μL of Neomycin. Cultured parasites were verified, 
by Giemsa stain, for the presence of healthy schizonts. The linearized targeting plasmid, 
containing the 5’ and 3’ UTR flanked by hDHFR cassette, and the AMAXA reagent were 
mixed with the naïve parasites schizonts and subjected to electroporation as described (43). 
Electroporated parasites were immediately mixed with ice-cold 1X PBS and intravenously 
injected into naïve mice. The mice were treated with Pyrimethamine beginning one day 
after parasite injection, for nine days to select for the mutant PbGRASP-KO parasites. 
PbGRASP-KO mutant parasites were isolated from the mice through cardiac 
puncture when the parasitemia reached 3-4%. Saponin (0.2%) was added to a sample of 
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the whole blood at a 1:2 ratio and placed on ice for 5 minutes. Samples were spun at 
5,900xg for 5 minutes and the resulting pellet was washed three times with 1 mL of PBS. 
The pellet was resuspended in 200 μL of 1X PBS, gDNA was prepared from the saponin 
lysed blood sample using the QIAampTM DNA Blood Mini Kit. Genomic DNA preps were 
used as a template for PCR to confirm the presence and directionality of the newly inserted 
hDHFR cassette, and absence of the PbGRASP gene. Primers 5, 6, 7, 8 (Chart 1) were 
designed to overlap the regions between the hDHFR cassette and the 5’ and 3’ UTRs for 
confirmation.  Primers 5 and 6 amplified a 1428 bp region overlapping the hDHFR cassette 
and 5’UTR. Primer 7 and 8 amplified a 1398 bp regions overlapping the hDHFR cassette 
and 3’ UTR. Additionally, gDNA was sequenced and run through NCBI BLAST to 
confirm the absence of the GRASP gene.  
Blood from one mouse that received transfected parasites was diluted and injected 
into 50 naïve mice at 0.5 parasites per mouse, to develop blood stage mutant clones. 16 
mice became positively infected, confirmed through blood smear. PCR amplification of 
the region between primers 5 and 8 was completed for all newly infected mice. All 16 mice 
were positively infected with the PbGRASP-KO mutants. Three clones (Clones 4, 13, and 
16) were selected for further characterization. 
Phenotyping the mosquito stage 
To assess whether the GRASP gene has an impact on the development of the 
parasite within the mosquito, female An. stephensi were infected with WT and PbGRASP-
KO parasites through controlled blood feeding, depicted in Figure 10. On day 17 p.i., 
infected female mosquito midguts were dissected and stained with 0.1% mercurochrome. 
Oocysts were counted immediately following dissection using a light microscope equipped 
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with a 40x objective. On day 22 p.i., salivary glands were dissected as described earlier 
and sporozoite yields were quantified. 
Gliding motility assay 
To assess whether the deletion of GRASP has an impact on sporozoite motility, we 
looked at the trails of CSP left by gliding sporozoites on a LabTek 8 well chamber slide. 
Dissected sporozoites were placed in the well chamber in RPMI 1640 culture medium for 
45 minutes in a 37°C incubator. The sporozoite trails were fixed with cold fixative solution 
(10X PBS supplemented with 10% formaldehyde, and 27% glutaraldehyde) and incubated 
at room temperature for 15 minutes. Wells were washed 3 times with 1X PBS and stained 
with a mouse anti-CSP (3D11) antibody and incubated at 4°C overnight. The secondary 
antibody, anti-Mouse IgG (Alexa-488), was applied the following day at a 1:1000 dilution. 
Gliding trials were visualized, and images acquired through an oil immersion 63x objective 
on a Zeiss fluorescence microscope and a Hamamatsu ORCA-R2 camera. 
Phenotyping the liver stage 
To characterize the phenotype of the liver stage, 10,000 GRASP-KO or WT 
sporozoites were injected intravenously into mice, outlined in Figure 10. The parasitemia 
was determined by counting infected RBC on blood smears taken every 24-h for 6 days 
p.i. starting from day 3 p.i. The parasites were quantified using a light microscope equipped 
with an oil immersion 100x objective. Morphology of the blood stage parasites was 
determined by quantifying the number of different erythrocytic stages such as rings, 
trophozoites, and schizonts at day 4 and 5 p.i. 
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Investigation of liver stages in vivo  
To further elucidate the role of GRASP in the liver stage of the parasite, an in vivo 
model was developed. As depicted in Figure 11, WT and PbGRASP-KO sporozoites were 
injected into mice at a dilution of 10,000 sporozoites per mouse. At 24, 40, and 72-h p.i., 
5 mice from each group were anesthetized and the whole liver was extracted. At 72-h p.i. 
liver was extracted after complete perfusion with 10 ml of 1X PBS. The liver samples were 
placed in 50 mL falcon tubes containing 12 mL of TRIzol as described (44). Using a Rotor-
Stator Homogenizer, liver samples were homogenized for 1 minute and placed in -80°C 
overnight. The samples were thawed at room temperature and vortexed for 30 seconds to 
let the layers of tissue and supernatant separate. From the supernatant, 1 mL aliquots were 
transferred to 1.5 mL microcentrifuge tubes. Samples were centrifuged for 10 minutes at 
12,000xg. Next, 500 μL of the resulting clear supernatant was transferred to a new 1.5 μL 
microcentrifuge tube and 500 μL of TRIzol was added to the sample and vortexed. Next, 
200 μL of chloroform was added to the reaction and tubes were shaken by hand for 15 
seconds and incubated at room temperature for 3 minutes. The samples were then placed 
on ice for an additional 3 minutes and centrifuged at 12,000xg for 15 minutes. The upper 
aqueous layer containing RNA was transferred to a new 1.5 mL microcentrifuge tube (~400 
μL) and the same volume of 70% ethanol was transferred to the sample, mixing the sample 
through pipetting. Seven hundred microliters of the mixture were used for RNA isolation 
using QuiagenTM RNeasy mini kit following the manufacturer’s instructions. RNA 
concentration was measured using a nanodrop and diluted to a 1μg/μL stock. 
Complementary DNA (cDNA) was synthesized from the single stranded RNA 
precipitated from the liver tissues samples following the SuperScript First-Strand Synthesis 
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System protocol by Invitrogen as described (44). Samples were stored at -80°C until further 
use.  
DNA standards were prepared by amplifying P. berghei gDNA with the Velocity 
DNA polymerase. The 18S gene was chosen to estimate parasite load and mouse β-actin 
was chosen to normalize the data. To 300 ng of template P. berghei gDNA, 10 μL of 5x 
Velocity buffer, 2 μL of primer dilution, 5 μL of 10 mM dNTPs, 1 μL of Velocity 
polymerase, 0.25 μL of dimethyl sulfoxide (DMSO), and nuclease free water up to total 
volume of 50 μL was added in a PCR tube for both β-actin and 18S samples. PCR was 
performed under the following conditions: initial denaturation of 98°C for 5 minutes, 
followed by 35 cycles of 98°C for 30 seconds, 50°C for 30 seconds, and 72°C for 30 
seconds. A final extension cycle of 72°C was performed for 7 minutes and samples were 
preserved at 4°C. PCR product size was confirmed by running the products on a 1% 
agarose gel with a 100 bp ladder to confirm band sizes of 134 bp for 18S and 154 bp for β-
Actin amplification. PCR products were cleaned using the QuiagenTM Column PCR 
Cleanup kit. 
Concentration of the 18S and β-actin PCR products were diluted to 1ng/μL using 
nuclease free water. Serial dilutions of 108, 107, 106, 105, and 104 of template DNA copies 
in 2 μL were generated for the standard curve. 18S (Primers 9, 10) and β-actin primer 
(Primers 11, 12) dilutions were prepared at a 1:1:18 dilution of forward primer, reverse 
primer, and nuclease free water as described (44) (Chart 1).  To create the master mix, 12.5 
μL of 2xSYBR Green PCR Master mix, 1.6 μL of β-actin or 18S primer dilution, and 8.9 
μL Nuclease-Free water is mixed for each individual well. 23 μL of master mix was added 
to each well in a 96 well plate, with 48 wells containing the β-actin primer master mix and 
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48 wells containing the 18S primer master mix. Standard curve DNA dilutions and the 
sample cDNA were added in triplicate to the respective wells in 2 μL volumes. For “no 
template added” wells, 2 μL of Nuclease-Free water was added. The plate was sealed with 
Microamp Optical Adhesive Film Cover and spun at 300xg for 2 minutes. The plate was 
placed in a thermal cycler and the following protocol was followed: 15 minutes at 95°C, 
40 cycles with 95°C for 20 seconds, 60°C for 30 seconds, and 72°C for 50 seconds. 
Quantifications were normalized to the mouse β-actin gene to overcome variability in the 
concentration of 18S cDNA. 
Investigation of liver stages in vitro  
Characterized in Figure 12, 1 mL of Hepa1-6 cells were added to a 15 mL falcon 
tube with 5 mL of cell medium (αMEM with 10% Fetal Bovine Serum (FBS), 2 mM of L-
Glutamine, 100 U/ml of Penicillin-Streptomycin, 0.25 μg/ml Fungizone). Cells were spun 
at 1500xrpm (Backman Coulter Allegra 6r centrifuge - GH-3.8 rotor)  for 5 minutes. 
Medium was discarded by vacuum to wash away excess DMSO from prior cell 
preservation steps. To the remaining cell pellet, 1.5 mL of cell medium was added to 
resuspend cell pellet. The cell mixture was added to a T25 flask. Cells were grown to 80% 
confluency, with cell medium changes every 24-h. To seed cells for infection, the cells 
were rinsed with 10 mL of pre-warmed 1X PBS. Next, 1 mL of trypsin was added along 
the cell layer and vacuumed out. Another 3 mL of trypsin was added to the cell layer, and 
the plate was moved to 37°C for 3-5 minutes to allow the cells to dislodge from the flask. 
Next, 9 mL of cell medium was added to stop the trypsin digestion. Cells were then 
transferred to a 15 mL falcon tube and spun for 5 minutes at 2000 rpm (Backman Coulter 
Allegra 6r centrifuge - GH-3.8 rotor). Post spin, the supernatant was vacuumed out and the 
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cells were resuspended in 5 mL of cell medium. To quantify the cells, a 1:1 dilution of 
resuspended cells was added to Trypan blue. Three 24-well plates, each containing 3 wells 
for WT and 3 wells for the PbGRASP-KO infection, were fixed with glass coverslips. Each 
plate is specific for cell fixation at 24, 48, or 67-h p.i. Cells were diluted and 100,000 cells 
in one mL were added to each well . Cell culture medium was changed every 24-h.  
Twenty thousand sporozoites in 500 μL of dissection media were added to each 
seeded well and spun at 2000 rpm (Backman Coulter Allegra 6r centrifuge - GH-3.8 rotor) 
for 5 minutes. The infection was prolonged for 3-h at 37°C and washed three times with 
1X PBS subsidized with 100U/mL of PS, and 0.25 μg/mL of Fungizone. Following the 
wash, 1 mL of cell medium was added to each well, and plates were returned to the 37°C 
incubator. Cells were fixed at different time points for IFA. For plates fixed past 24-h, cell 
medium was changed every 24-h, subsidized with 0.12 μg/ml of Mycamine. 
Immunofluorescence assays (IFA) 
At 24, 48, and 67-h p.i., wells were washed with 500 μL of 1X PBS and fixed with 
250 μL of fixative solution (5 mL water, 1 mL of 10X PBS, 4 mL 10% formaldehyde, 8 
μL 27% glutaraldehyde) then incubated at room temperature for 15 minutes, wrapped in 
aluminum foil to minimize light exposure. Following incubation, cells were washed twice 
with 1X PBS. Fixed cells were then permeabilized with 0.3% Triton X-100 in 1X PBS and 
incubated at room temperature for 5-7 minutes. Cells were washed twice with 1X PBS and 
placed in a blocking solution; 300 μL of 3% BSA in 1X PBS per well, and incubated 
overnight at 4°C.  
Detection was performed with mouse anti-HSP70 (4C9), rat anti-ATG8, and rabbit 
anti-TRAP in 3% BSA in 1X PBS. Following primary antibody incubation, wells were 
 22 
washed three times with 1X PBS (5 minutes/wash) and secondary antibodies were added 
to 3% BSA in 1X PBS; anti-mouse (Alexa-555), anti-rabbit (Alexa-647), and anti-rat 
(Alexa-488) (diluted at 1:1000). Plates were wrapped in aluminum foil and incubated at 
room temperature for 45 minutes, followed by a wash step with 1X PBS (5 minutes/wash). 
DAPI stock was diluted to 1 μg/mL and added to wells at a 1:1000 dilution and incubated 
for 5 minutes, followed by three wash steps with 1X PBS. Coverslips were removed and 
rinsed in 1X PBS and water before mounting onto a slide with 3 μL of ProLong Diamond 
antifade mounting solution. Slides were stored at 4°C in the dark until imaging.  
Infected cells were visualized with the Zeiss microscope equipped with an oil 
immersion 100x objective and a Hamamatsu ORCA-R2 camera. Optical Z-sections with a 
0.2 μm spacing were captured using the Volocity software. Images were deconvolved using 
an iterative restoration algorithm. Contrast of individual images was adjusted using 
Volocity software. Using the Volocity software, deconvolved images showing HSP70 
fluorescence were used to obtain data on the average volume and area of WT and 
PbGRASP-KO. Using Volocity Software, DAPI fluorescence overlapping with HSP70 
fluorescence was used to obtain the mean fluorescence intensity of the parasite’s nucleic 
acid content. 
Phenotyping the blood stage 
To determine whether the GRASP gene has a functional role in blood stage 
development of Plasmodium, 0.01% of PbGRASP-KO or WT P. berghei infected blood 
was injected intravenously into two sets of mice, as depicted in Figure 10. The parasitemia 
was monitored for five days. Parasitemia was determined by counting infected red blood 
cells on blood smears taken every 24-h for 5 days p.i. The parasites were observed and 
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quantified, after Giemsa staining of blood smears, using a light microscope equipped with 
an oil immersion 100x objective. 
Electron microscopy (EM) 
For transmission EM, sporozoites isolated from mosquito salivary glands were 
maintained in Dulbecco's Modified Eagle Medium (DMEM) and 10% FBS for 12-h at 
37oC. Blood collected from infected mice was washed 3x in 1X PBS, fixed in 2.5% 
glutaraldehyde (EM grade; Electron Microscopy Sciences, Hatfield, PA) in 0.1 mM 
sodium cacodylate buffer (pH 7.4) for 1 hour at room temperature, and processed as 
described (45) before examination with a Philips CM120 Electron Microscope (Eindhoven, 








As we hypothesized that GRASP might be playing an important role as a 
component of autophagic organelle clearance during liver-stage development of 
Plasmodium, deletion of the GRASP gene would have an observable impact on the 
metamorphosis of the Plasmodium parasite. However, our goal was to study the effect of 
the GRASP gene deletion, using P. berghei as a model parasite, through all stages of the 
parasite’s life cycle in order to identify GRASP function.  
 
1. Successful generation of a PbGRASP-KO strain 
Four sets of transfections of the PbGRASP-KO construct were completed 
(Figure 6), and transfected parasites were injected into 4 individual mice, the 
transfection process is illustrated in Figure 7. After 9 days of drug treatment, 
parasites were harvested and gDNA from a fraction of the parasite population was 
isolated for further verification. Successful integration of the deletion construct was 
verified by PCR with primer pairs 5/6 (for 5’ UTR) and 7/8 (for 3’ UTR). As shown 
in Figure 8, amplification of a 1428 bp fragment with primer pair 5/6 and a 1398 
bp fragment with primer pair 7/8 suggests the successful integration of the deletion 
construct into the parasite genomic locus. Additional smaller bands in Figure 8 
suggests a mixed parasite population that required further cloning into individual 
parasite clones. For cloning, we infected 50 mice with 0.5 parasite/mice from one 
of the 4 transformant infected mice. Of the 50 mice infected with 0.5 mutant 
parasites per mouse, 16 became infected. Initial confirmation of a positive infection 
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was completed with Giemsa stained blood smears. The generation of the 
PbGRASP-KO was further confirmed by PCR of the transfected parasites, using 
primer pair 5/8 to amplify the 3981 bp region overlapping the 5’ UTR, hDHFR 
selection cassette, and the 3’ UTR (Figure 6). Primer 5 and primer 8 were designed 
from upstream of the 5’ UTR (Primer 5) and downstream of the 3’ UTR (Primer 
8). An amplification of 3981 bp not only confirms the integration of the plasmid 
but also its integration in the right locus. Figure 9 illustrates this verification with 
all 16 mice expressing a PCR band slightly below 4 kilobases (kb). This assay 
provided confirmation that our mice were infected with the mutant PbGRASP-KO, 
and the blood stage of the parasite could be isolated for future work. 
 
2. The PbGRASP-KO strain develops normally in mosquitoes  
To investigate whether the GRASP gene deletion affects the development 
of P. berghei in the mosquito or has an impact on the quality of the infection. We 
infected An. stephensi mosquitoes by feeding on WT and PbGRASP-KO infected 
mice. On day 17, we dissected the mosquito midguts of WT and PbGRASP-KO 
(clone 4) infected mosquitoes (n=30) to quantify oocysts, and we observed that the 
difference in the oocyst yield was not significant (Figure 13A). PbGRASP-KO 
oocysts developed similarly to WT, and the intensity of the infection was not 
statistically significant between the two groups. On day 23 p.i., we dissected the 
salivary glands (n=30) from the same infection groups and quantified the average 
yield of sporozoites per female mosquito. We observed that the salivary gland 
sporozoite load was similar in WT and PbGRASP-KO clones 4 and 16. The 
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difference in the average number of sporozoites per female (14, 375 WT; 20,125 
clone 4; 19,100 clone 16) was not significant when using the Mann-Whitney U test 
to compare each clone to WT (Figure 13B). 
 
3. CSP trail left behind by PbGRASP-KO suggest that sporozoites are motile 
We next examined whether GRASP is involved in the parasite motility. 
Sporozoite motility requires CSP expression through the secretory pathway and 
exposure at the plasma membrane, therefore GRASP deletion could impact 
secretion of CSP to the sporozoite plasma membrane. An IFA was conducted to 
visualize the trails of CSP left by gliding motile sporozoites. We observed that both 
PbGRASP-KO and the WT strain left similar swirling, circular random trails of 
CSP, shown in Figure 14, indicating that the PbGRASP-KO strain remained motile 
in the sporozoite form, and CSP was secreted by both strains. 
 
4. PbGRASP-KO sporozoite infection leads to enhanced blood stage infection at day 
5 p.i. 
To investigate whether GRASP plays a role in the development of P. 
berghei in the liver, we injected 10,000 WT or PbGRASP-KO sporozoites 
intravenously into naïve mice, and monitored the parasitemia and prepatent period, 
namely the emergence of the parasite in the blood, for 6 days p.i.. Illustrated in 
Figure 15, on day 3 p.i., we observed that both WT and PbGRASP-KO strains did 
emerge from the liver stage into the blood stage but with fewer PbGRASP-KO 
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parasites; however, this value was not statistically significant according to a Mann 
Whitney U test.  
On day 4 p.i., the PbGRASP-KO infected mice experienced a spike in 
parasitemia that surpassed the WT infection. The PbGRASP-KO infected mice 
continued to have an enhanced parasitemia that continuing from day 4 to day 6 p.i. 
On days 5 and 6 p.i., the PbGRASP-KO parasitemia was significantly higher from 
the WT when using the Mann-Whitney U test. We have tested this assay with more 
than one clone of PbGRASP-KO and observed the same parasitemia growth pattern 
(clones 4 and 16).  
To provide more clarity on a potential phenotype during the emergence 
period from the exoerythrocytic stage to the erythrocytic stage, we analyzed the 
morphology of the blood stage parasites on day 4 and 5 p.i. after a sporozoite 
infection. Analysis of PbGRASP-KO (clone 16) showed a statistically greater 
number of rings compared to WT at day 4 (p=0.0317) and 5 p.i. (p=0.0312) (Figure 
16).  
 
5. Quantification of the parasite burden in the liver at different time points post 
infection 
To determine whether the phenotype we observed in the prepatent period 
after a sporozoite infection is the result of a slight delay in the release of majority 
of the hepatic merozoites and/or determine if more hepatic merozoites are being 
produced during late liver stage, we infected mice with 10,000 sporozoites and 
harvested liver from infected mice at 24, 40, and 72-h p.i.. We amplified parasite 
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18S cDNA by quantitative Real Time PCR (qRT-PCR) to estimate the liver parasite 
load and normalized it with host b-Actin. As we saw the difference in parasitemia 
on day 4 p.i. onwards after sporozoite injection, we expect at 24-h both WT and 
PbGRASP-KO to have similar parasite load. If there is a difference in schizogony, 
we will assume a measurable difference at the 40-h time point. Otherwise, if there 
is a subtle delay in release of most of the merozoites by PbGRASP-KO, we expect 
to see a significant difference between WT and PbGRASP-KO at 72-h p.i. 
Surprisingly, we observed no difference in the liver parasite load between 
PbGRASP-KO and WT parasites at any time points (Figure 17). This suggests there 
is no difference in schizogony in the liver stage. However, the subtle delay in 
merozoite or merosome release might need measurement of liver parasite burden 
at multiple time points between 55-h and 72-h as merozoites starts to come to blood 
around 55-h in WT parasite. 
 
6. WT and PbGRASP-KO mutant produces similar yield of the exoerythrocytic forms 
(EEFs)  
We next investigated if GRASP could contribute to invasion of sporozoites 
to hepatocytes and/or egress of merozoites from hepatocytes in vitro. The number 
of EEFs were calculated by IFA at 24, 48, and 67-h p.i. of Hepa1-6 cells, and 100 
fields of WT and PbGRASP-KO infected cells were analyzed at each time point. 
At 24, 48, and 67-h p.i., no difference in the average number of EEFs between WT 
and PbGRASP-KO was observed according to the Mann-Whitney U test (Figure 
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18). This suggests no obvious defects in parasite invasion and egress in the absence 
of GRASP.  
 
7. At 24-h p.i., PbGRASP-KO liver stage parasites are larger than WT 
Next, by IFA we analyzed the average volume of the PbGRASP-KO EEFs 
as they grew from 24 to 67-h p.i. in vitro. We observed a statistically significant 
difference (Median volume of 215.2 µm3 vs 191.2 µm3; p=0.0225) in parasite 
volumetric area at 24-h p.i. but not significant at 48-h or 67-h when using the Mann-
Whitney U test (Figure 19). This suggests the early transformation in PbGRASP-
KO parasites might be rapid as compared to the WT. 
 
8. The surface area of PbGRASP-KO parasites was not significantly different from 
WT parasites 
To further investigate if the PbGRASP-KO affected growth, the surface 
area of processed images was obtained using HSP70 staining at 67-h p.i.. The 
difference in the area of PbGRASP-KO and WT was not significant when using the 
Mann-Whitney U test (Figure 20). This suggests both WT and PbGRASP-KO 
parasites are developing normally in vitro. 
 
9. Karyokinesis is normal in PbGRASP-KO and WT schizonts in the liver 
To examine if there was more hepatic merozoite formation in PbGRASP-
KO, we quantified the total fluorescence intensity of DAPI, a measure of the nucleic 
acid content of the developing parasite, as the PbGRASP-KO developed in vitro at 
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48-h p.i. We observed that the total fluorescence intensity of the PbGRASP-KO 
nucleic matter was not statistically significant from WT when using the Mann-
Whitney U test (Figure 21). This suggests that both WT and PbGRASP-KO parasite 
have similar number of nuclei at 67h schizont stage. 
 
10. PbGRASP-KO parasites compartmentalize micronemes for elimination 
We next hypothesized that GRASP could be involved in microneme 
clearance from converting sporozoites according to our model in Figure 3. Hepa1-
6 cells were infected with WT and PbGRASP-KO parasites and fixed at 24, 48, and 
67-h p.i. to examine the fate of micronemes using anti-TRAP antibodies. Depicted 
in Figure 22, at 24-h p.i., fluorescence imaging shows TRAP staining of distinct 
and well-defined puncta, close to the parasites’ surface membrane. In the WT 
parasite, the TRAP staining was more dispersed throughout and did not appear to 
be forming clear well-defined puncta (n=35). By 48-h p.i., TRAP could still be seen 
distributed across the WT and PbGRASP-KO parasites, while some of the TRAP 
had begun to congregate near the surface of the parasite or in the PV space (Figure 
23). Interestingly, the TRAP staining was observed outside of the PV in both WT 
and KO, a possible indication that TRAP staining illuminated PVM evaginations 
into the host cell cytosol.  At 67-h p.i., TRAP has almost entirely been expelled into 
the PV of both WT and PbGRASP-KO strains (Figure 24). We also performed 
ATG8 staining using anti-ATG8 antibodies. ATG8 and TRAP signals were seen in 
partial colocalization from 24 to 67-h p.i., suggesting an elimination of micronemes 
through exophagy in both lines. Additionally, at 67-h p.i. ATG8 staining appears 
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to be in branched structure reminiscent of the apicoplast organelle, a possible site 
for the derivation of proteins for phagophore assembly (Figure 24). The IFA image 
data reveals that unexpectedly, GRASP does not play an essential role in the 
process of microneme clearance from liver forms.  
We then performed EM observations on PbGRASP-KO sporozoites 
maintained under axenic conditions in culture medium for 12-h (7, 46). The process 
of conversion is initiated with the dismantling of the IMC that corsets the parasite 
and the IMC detachment from the parasite plasma membrane, which allows the 
parasite to expand in size and volume (Figure 25 – A, panel a). Micronemes are 
then sequestered in a double sac membrane in the parasite cytosol (Figure 25 –A 
panel b). We observed these same steps in KO parasites: the dissociation of the 
IMC from the parasite plasma membrane (Figure 25 – B, panels a-c), the 
compaction of the IMC in the cytoplasm (Figure 25 – B, panels d and e) followed 
by expulsion into the environment (Figure 25 – B, panel f) and sequestration of 
micronemes into a double membrane structures (Figure 25 – B, panel g). These 
observations further indicate that GRASP is not essential for any of the conversion 
steps, as PbGRASP-KO parasites convert normally into liver forms. 
 
11. The PbGRASP-KO strain has a normal replication rate in the blood  
Previous studies have analyzed the GRASP ortholog in P. falciparum. 
Using RT-PCR, PfGRASP expression was observed across the asexual blood stage 
(42). A study using PfGRASP antibody showed that GRASP remained within the 
parasite throughout the asexual period, and colocalized with the cis-Golgi marker 
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ERD2 (ER-retention-defective complementation group 2) (42). The expression of 
GRASP during the blood stage lead us to investigate whether the development of a 
blood stage infection would be dysregulated or impaired in a PbGRASP-KO strain 
compared to WT parasites. To assess the development of the KO in the blood, we 
injected equal numbers (0.01% final parasitemia) of erythrocytic forms of 
PbGRASP-KO or WT parasites into naïve mice and monitored the replication of 
PbGRASP-KO and WT parasite by measuring parasitemia for 5 days p.i. on blood 
smears. Detailed in Figure 26, the parasitemia of both groups developed equally 
overtime. This study was repeated for three PbGRASP-KO clones (clones 4, 13, 
and 16). The same growth pattern was observed for all clones which is similar to 
WT parasites. For blood stage comparison, One-way ANOVA/Kruskal-Wallis 
Test: P>0.999 was used.  Each PbGRASP-KO clone was tested against WT with a 
Mann-Whitney U test. Finally, we inspected the morphology and organellar content 
of PbGRASP-KO in the blood stage by EM. Similar to WT parasites, the KO strain 
exhibited a normal ultrastructure, without cytopathies (Figure 27). Maurer's clefts, 
membranous tubular structures secreted by the parasite and dispersed in the host 
RBC cytoplasm, were also observed, indicating that GRASP seems not involved in 






As it cycles between hosts, Plasmodium must adapt to new environments within 
the definitive mosquito host and a vertebrate host. The adaptation to these environments is 
mediated by dramatic transformations reliant on autophagy, to adjust parasite morphology 
and metabolism (10).  The secretory autophagy pathway for organelle remodeling is 
critically important for the metamorphosis and development of Plasmodium parasites in 
the liver. 
 We hypothesize that an unconventional organelle expulsion pathway may be 
utilized in sporozoites during conversion into replicative liver forms. We previously 
illustrated that this process involves Plasmodium ATG ubiquitous genes that help in the 
formation of ATG8- associated autophagosome structures that engulf organelles to be 
discarded (10). To provide additional information on this pathway and identify other 
molecular effectors, we have investigated the role of Plasmodium GRASP, a major player 
in the UPS pathway in many organisms (13, 39).  
 We hypothesize that GRASP could function in the secretory autophagy pathway of 
Plasmodium during morphological transformations between hosts and tissues. We have 
explored the P. berghei GRASP function by selectively deleting the GRASP gene 
(PbGRASP-KO) and phenotyping a PbGRASP-KO mutant through all stages of the 
parasite’s life cycle.  
The first stage we investigated was the development of the PbGRASP-KO strain in 
the mosquito host. To investigate whether the PbGRASP gene has a potential impact on 
the growth of Plasmodium within the midgut epithelium of a female mosquito, or can 
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impact the quality of the mosquito infection, the PbGRASP-KO parasites were monitored 
through the mosquito host for 21 days p.i. Quantification of the PbGRASP-KO oocysts on 
day 17 and sporozoite forms on day 21, together they indicate that there is no difference in 
the average oocyst or sporozoite numbers compared to the WT strain (Figure 13). The 
similarity in average yields suggests that PbGRASP does not have a significant impact on 
gametocyte fusion in the midgut, ookinete motility into the mosquito midgut epithelium, 
development of oocysts, asexual replication of sporozoites, or sporozoite motility and 
invasion of the salivary glands.  
Additionally, we wanted to determine whether PbGRASP could impact the motility 
of the salivary gland sporozoite. Gliding motility is a characteristic that is essential in 
hepatocyte invasion by the sporozoite. Evaluation of CSP trails left behind by a motile 
sporozoite suggests that the PbGRASP-KO strain remains motile. Furthermore, the liver 
stage burden at 24 and 40-h p.i. by qRT-PCR, as well as the IFA images at 24-h p.i., suggest 
the PbGRASP-KO strain has no defect in motility, as it is equally infectious as WT (Figures 
17, 24). This suggests that CSP secretion is not reliant on GRASP, GRASP does not 
participate in sporozoite motility during tissue traversal to reach the host liver, nor does the 
absence of GRASP result in a defect in motility. 
Of primary interest was the role of PbGRASP in the liver stage. Previous studies 
show that the PbGRASP gene is expressed throughout the liver stage of the parasite (3 days 
p.i.) indicating a potential role for GRASP during this period of metamorphosis (10). The 
transformation from the invasion-competent sporozoite to a metabolically active 
trophozoite and schizont within a hepatocyte requires the parasite to transition from an 
arthropod to vertebrate cellular environment. To achieve this transformation, Plasmodium 
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expels superfluous micronemes that are no longer required for parasite survival after 
invasion of the hepatocyte (7). If the GRASP gene is expressed and has a role in the 
exophagy pathway during liver stage development, the PbGRASP-KO strain may not 
emerge into the blood at all or may be defective or delayed in blood stage infection.  
Further examination of Plasmodium liver stage development is critically important, 
as it precedes the clinically relevant blood stage. The transfer of a sporozoite through the 
bite of a mosquito presents a bottleneck event for Plasmodium, as few sporozoites enter 
the bite site, a reported a mean of 123 sporozoites per bite, and a geometric mean of 36 
sporozoites per bite (47). This bottleneck suggests that the asexual schizogony period 
within a hepatocyte is important for increasing parasite numbers and establishing infection 
within the vertebrate host. We hypothesize that for the liver stage, a phenotypic difference 
may appear when comparing the PbGRASP-KO strain to WT.  
Evaluation of time to blood stage infection after injection of mice with WT or 
PbGRASP-KO sporozoites reveal that both strains began to emerge into the blood on day 
3 p.i. This suggests the time required to blood stage infectious forms is similar in both WT 
as well as PbGRASP-KO parasites (Figure 15). However, the parasitemia started to 
diverge, the PbGRASP-KO strain having more parasitized RBC than WT from day 4 p.i.. 
From this point on, PbGRASP-KO infected mice had significantly higher parasitemia and 
remained high until day 6 p.i. (the last day of blood smear collection) (Figure 15). This was 
interesting, because when we later studied the effect of PbGRASP-KO on blood stage 
development, we found the pattern and rate similar to WT (Figure 26).  This suggests that 
the phenotype is either derived from the liver stage or early blood stage. 
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One possible explanation is that while both strains lead to blood stage infection on the same 
day, some portion of the PbGRASP-KO liver stage parasites egress into the blood in a 
delayed manner, leading to a high blood stage infection starting on day 4 p.i. (Figure 15), 
which is supported partly by the statistically higher percentage of ring stage parasites in 
PbGRASP-KO than WT at day 4 and 5 p.i. (Figure 16). However, this is not supported by 
the quantification of parasite gene expression in the liver using qRT-PCR at 72-h p.i. This 
discrepancy might be due to the low initial parasite number or the time point selected for 
liver load estimation. We need to have multiple time points between 55h and 72h to 
effectively pin-point the difference in merozoite release. Additionally, the 18S gene 
selection could be replaced with the merozoite surface protein gene (MSP1). MSP1 can 
provide a more accurate parasite expression in the 40-72-h window, as at this stage 
Plasmodium has already differentiated to merozoite forms, which will allow us to better 
interrogate the late liver stage load. Additionally, a bioluminescent PbGRASP-KO would 
be helpful in continuous measurement of parasite liver load in real time. 
To continue characterization of the observed liver stage phenotype, an in vitro liver 
stage culture was developed to observe the development of the exoerythrocytic forms over 
time by fluorescence microscopy. We showed that the PbGRASP-KO strain develops 
normally, with no observed major growth defect. However, up to 24-h p.i., PbGRASP-KO 
strain has a significantly larger volumetric area, without any increase in nuclear profiles 
(Figures 24, 25, 26, 27). Together this data suggests that there is not enhanced hepatic 
merozoite production in the PbGRASP-KO strain, which is in line with our in vivo assay 
results, indicating that the root of the enhanced blood stage infection may lie outside of the 
liver stage altogether. However, to further confirm that there is no increase in the number 
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of nuclei, an assay to amplify parasite nucleic acid through qRT-PCR would be more 
informative. Furthermore, evaluation of the development of hepatic merozoites in the first 
round of replication in RBC would be of interest to understand the difference observed 
between PbGRASP-KO and WT parasitemia after sporozoite injection. We hypothesize 
the role of hepatic merozoites in enhanced parasitemia in PbGRASP-KO because they are 
transcriptionally significantly different than blood stage merozoites and might result in a 
differential first cycle of parasite replication (48). 
Of primary interest was observing whether PbGRASP is playing a role in the 
secretory autophagy pathway through the interaction with ATG8, to expel micronemes. 
Interestingly, the PbGRASP-KO strain appears to have more distinct, clear puncta of 
TRAP at 24-h p.i. This is suggestive that, at 24-h p.i., the PbGRASP-KO strain has better 
microneme compartmentalization than WT (GRASP-independent process), and the puncta 
are accumulated close to the parasite membrane surface, with a delay in microneme 
expulsion (possible GRASP-dependent process). One hypothesis for the PbGRASP-KO 
strain containing clearer puncta at 24-h could be that GRASP deletion results in an inability 
or stall in the tethering of amphisome structures to the parasite plasma membrane, resulting 
in a congregation of these vesicles near the surface. This hypothesis would be in line with 
what has been observed in D. discoideum (13, 39). Alternatively, GRASP, if involved in 
exophagy of micronemes, may act as a regulator, and in its absence in the KO, the 
sequestration of micronemes into autophagosomes and the delivery of autophagosomes to 
the plasma membrane could occur faster than in WT parasites. At 48 and 67-h p.i., we 
identified no other observable phenotypic difference when comparing the TRAP staining 
of PbGRASP-KO to WT during the in vitro infection. Successful clearance of micronemes 
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was observed in both the PbGRASP-KO and WT strain, indicating that GRASP does not 
have an essential role in microneme clearance as suspected initially. We also show that the 
PbGRASP-KO strain develops normally, with no observable growth defect (Figures 20, 
21, 22). No ultrastructural defect was seen in the in vitro conversion of PbGRASP-KO 
sporozoites to trophozoites, the IMC and micronemes could be further observed during 
expulsion into the PV (Figure 25). 
 Previous studies observing autophagy of P. falciparum in the blood identified that 
ATG8, an autophagosome marker and ubiquitous protein in the autophagy pathway, 
associated with autophagosome-like vesicles during periods of blood stage starvation or 
drug stress (49). This suggests that the formation of autophagosome-like structures for 
conventional autophagy or secretory autophagy (exophagy), occurs in the blood stage of 
the parasite. Additionally, GRASP expression is present across the asexual blood stage of 
P. falciparum (42).  If GRASP proteins participate in a secretory autophagy pathway, it is 
therefore plausible that in the absence of GRASP, this pathway could be dysregulated, and 
the Plasmodium infection cycle impaired, as the parasite is undergoing morphological 
transformations from merozoite to erythrocytic schizont forms between RBC infection, 
replication, and egress. 
By infecting erythrocytic forms of the PbGRASP-KO and WT strains into mice, 
we observed that the PbGRASP-KO strain is able to develop identically to the WT strain 
in the blood, with similar parasitemia levels at days 2, 3, 4, and 5 p.i. as the WT (Figure 
26). This study suggests that the deletion of the Plasmodium GRASP gene does not affect 
the growth and development of an established blood stage, nor does it affect the 
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maintenance of a blood stage infection over time. No ultrastructural defect could be 
observed in the KO blood stage parasites (Figure 27). 
At this time, we have eliminated several points in the Plasmodium life cycle as 
potential areas where the GRASP gene may have an impact on the parasite development. 
The only phenotype we observed is the PbGRASP-KO strain parasitemia spike beginning 
on 4 days p.i. of a sporozoite infection. This assay has been repeated three times with 
separate clones, all producing the same results.  We have not identified the reason for the 
enhanced blood stage infection induced by a sporozoite infection; however, we have further 
hypotheses that will guide future research.  
It is possible that the higher blood stage parasitemia phenotype in the KO is due to 
enhanced replication of hepatic merozoites during the first round of schizogony in RBC 
after invasion of a hepatic merozoite. This could be possible if GRASP acts as a regulator 
to erythrocyte stage schizogony. The normal egression of the PbGRASP-KO into the 
blood, followed by the spike in parasitemia from day 4 to 6 p.i., could be explained by this 
enhanced replicative step. In order to further investigate this phenomenon, we could 
perform cardiac puncture of infected mice with the WT and KO strains 55-h p.i., followed 
by culturing of infected RBC, bringing the first round of erythrocytic blood stages to 
schizonts, and enumerate mononucleated merozoites per schizonts through microscopy and 
flow cytometry assays (FAC). This assay would be possible because rodent parasites do 
not reinvade fresh RBC during in vitro culture conditions and remain stuck in the schizont 
stage. This will allow us to determine if the first round of erythrocytic production of 
merozoites is dysregulated or enhanced. Additionally, evaluation of the merosomes, a life 
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stage we have not yet characterized for our PbGRASP-KO strain, to observe size, number, 
and egress would possibly shed light on the observed phenotypic difference. 
Additional future plans include the development of an anti-GRASP antibody for 
the P. berghei ANKA strain. This will allow us to analyze the distribution of GRASP in 
all parasite stages, observe potential alterations in the Golgi morphology and assess 
whether the GRASP signal is associating with autophagy proteins, ATG8, and microneme 
proteins through colocalization, thus inform if GRASP intersect with the secretory 
autophagy machinery on liver forms.  
To repeat the assays we have completed thus far, a new host model should be 
chosen. Pb-ANKA has differential RBC preference depending on the host. In general, the 
ANKA strain has a preference for the invasion of reticulocytes. However, in the mouse 
model we used, Swiss Webster, few reticulocytes are present, and the strain defaults to the 
invasion of normocytes. This is significant because the cell types the parasite invades will 
dictate the number of merozoites per schizont. With this in mind, we will need to repeat 
our experiments with Wistar rats, a host model that will allow our strain to mostly infect 
reticulocytes, removing the possibility that our assay is skewed by the differences in 
parasitized cell types.  
Future research of the P. berghei GRASP gene would also benefit through 
exploitation of a luciferase expressing PbGRASP-KO mutant to observe the liver stage 
infection in live animals. Additionally, we hope to use flow cytometry to measure 
parasitemia in the blood of sporozoite inoculated mice, as it can more accurately detect low 
parasitemia. Both assays would allow us to better follow the PbGRASP-KO emergence 
from liver to blood in vivo and in vitro infections, so as to identify if a subtle merozoite 
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Figure 1 The Plasmodium Life Cycle 
The Plasmodium parasite cycles between a definite female mosquito host and a vertebrate 
intermediate host. 
Mosquito host: During a blood meal, the female mosquito ingests gametocytes, the sexual 
stage of the Plasmodium parasite. The gametocytes release gametes. Male and female 
gametes fuse in the midgut of the mosquito forming a zygote, which metamorphosed to a 
motile ookinete. The ookinete is motile and traverses the midgut epithelium. On the basal 
surface of the midgut epithelium, the ookinete transforms into an oocyst. Asexual 
reproduction within the oocyst generates the sporozoite stage of the parasite. Sporozoites 
burst from the oocyst and travel forward to the salivary glands of the mosquito, penetrating 
and invading the salivary gland tissues. Once in the salivary gland, the sporozoites 
undergoes final developmental changes and waits for the mosquito to take a blood meal. 
Vertebrate host: During a mosquito blood meal, the sporozoite enters the host dermis, and 
migrates to the blood. The slender sporozoite now is carried to the host hepatocyte, where 
it can invade and undergo necessary replicative steps. The sporozoite transforms into a 
metabolically active trophozoite. Through the process of schizogony the trophozoite 
transforms into a hepatic schizont. When schizogony is completed, the schizont bursts from 
the hepatocyte, releasing merosomes packed with mononucleated merozoites into the 
blood. Hepatic merozoites invade RBCs, transforming through erythrocytic trophozoite 
and schizont forms. Schizonts lyse the RBC’s and the infection continues with erythrocytic 
merozoites invading new RBCs. Some of the blood stage parasites differentiate into 
















































Figure 2 - Clearance of TRAP-containing micronemes from transforming sporozoite 
A GFP-expressing P. berghei parasite within a Hepa1-6 cell is observed by fluorescence 
microscopy. Following invasion of the hepatocyte, the sporozoite begins to undergo 
dramatic morphological transformations from a slender and invasion competent sporozoite 
to a round, metabolically active trophozoite. At 1-h the TRAP signal with an anti-TRAP 
antibody (red) looks diffuse due to the small size of micronemes (25 nm diameter) that are 
dispersed throughout the cytoplasm of sporozoites, By 4-h p.i., the sporozoite begin to 
round in the center, drawing the distal ends of the pointed sporozoite inward. TRAP is still 
uniformly dispersed across the parasite surface at this time.  At 10-h p.i., the TRAP begins 
to compartmentalize into distinct puncta, reflective of micronemes sequestered into 
autophagosomes. At 22-h p.i., the TRAP signal begun to be in the parasitophorous vacuole 
(PV). By 36-h p.i., the microneme TRAP has been almost entirely eliminated from 


















































Figure 3 – A hypothetical model of the P. berghei Secretory Autophagy Pathway 
I. ATG8-containing vesicles or tubules bud off from the apicoplast organelle.  
II. ATG8 form cup-shaped phagophore that surrounds cytoplasmic contents, such as 
micronemes. 
III. The phagophore continues to expand, forming an autophagosome vesicle, isolating 
micronemes 
IV. GRASP proteins tether multivesicular bodies (MVB) and autophagosomes together, 
fusion induces the formation of an amphisome 
V. GRASP tethers amphisome to plasma membrane, dumping microneme protein cargo 
















Figure 4 - GRASP establish the stacked cisternae structure of the mammalian Golgi 
complex  
Myristoylation of the N-terminus on mammalian Golgi Reassembly and Stacking Proteins, 
GRASP55 and GRASP65 facilitate the tethering of Golgi cisternae into the stacked 
cisternae Golgi complex. Arrows in blue pinpoint the location of the GRASP proteins 































Figure 5 - Expression of P. berghei GRASP at 1, 2, and 3 days p.i. in the liver forms 
Expression of PbGRASP in liver stage was measured in duplicate by RT-PCR over 1, 2, 
and 3 days p.i. GAPDH expression was used as an internal control. GRASP and GAPDH 
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Figure 6 - Homologous recombination strategy for the generation of the PbGRASP-
KO mutant 
PbGRASP-KO plasmids was constructed with the E. coli cloning vector pDEF. hDHFR in 
the plasmid is the selection marker for the selection of mutant parasite. Homologous 
sequence arms, the 5’ and 3’ UTRs were amplified from P. berghei gDNA by PCR. 
Through homologous recombination, the PbGRASP gene was replaced by the human 
dihydrofolate reductase selection marker. Primers 5 and 6, flanking the 5’ UTR, and 
Primers 7 and 8, flanking the 3’ UTR, were used to confirm the presence of the hDHFR 














Figure 7 - Generation of PbGRASP-KO parasites through transfection 
Naïve female Swiss-Webster mice were intraperitoneally infected with WT P. berghei 
ANKA parasites. When parasitemia reached 3-4% a cardiac puncture was performed, and 
blood was transferred to culture in 1640 RPMI culture medium for 22 hours at 37°C with 
a constant shaking at 80 rpm. The recombinant plasmid DNA and the AMAXA reagent 
were introduced to the parasite culture and subjected to electroporation. The transfected 
parasite containing WT and PbGRASP-KO mutants, were intraperitoneally infected into 
naïve mice. The mice were treated with Pyrimethamine for nine days to kill remaining WT 
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Figure 8 - PCR confirmation of PbGRASP-KO  
Following the generation of the PbGRASP-KO strain through transfection, PCR of saponin 
lysed blood containing erythrocytic forms of the parasites was used to confirm the presence 
of the hDHFR cassette in samples from 4 infected mice. Primers 5 and 6 amplified a 1428 
bp region that overlapped the 5’UTR and the hDHFR cassette. Primers 7 and 8 amplified 
a 1398 bp region overlapping the 3’ UTR and the hDHFR cassette. PCR products were run 
by gel electrophoresis. All four mice were confirmed to be positively infected by the 
PbGRASP-KO mutant. Genomic DNA from a WT infected mouse was used as control and 
showed no PCR amplification. L1: 1 kb DNA ladder, L2: 100 bp DNA ladder, M1-M4: 
Mouse receiving transfected parasite. WT: Wild type. 
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Figure 9 - Generation of PbGRASP-KO blood stage clones 
Fifty Swiss-Webster mice were infected with the PbGRASP-KO strain, receiving an 
infection dose of 0.5 parasites per mouse. 16 mice were initially confirmed to be infected 
by blood smear. Primers 5 and 8 were chosen to amplify a 3981 bp region from the 5’ UTR 
to the 3’ UTR. PCR products were run by gel electrophoresis. All 16 mice were positively 
confirmed by PCR to be infected with the PbGRASP-KO mutant parasite. The green dots 
pinpoint the clones (4, 13, 16) that were selected for further characterization because no 








Figure 10 - Methodology to phenotype the blood, mosquito, and liver stage 
development of P. berghei 
Mosquito Stage: Two groups of Anopheles stephensi mosquitos were infected through 
blood feeding on WT or PbGRASP-KO infected mice. On day 17 p.i., mosquito midguts 
were dissected, and oocyst yields were quantified through light microscopy. On day 23 p.i., 
salivary glands were dissected and the average sporozoite yield per mosquito was 
quantified. Liver Stage: WT and PbGRASP-KO infected An. stephensi were dissected, 
isolating the sporozoites. Two groups of naïve mice were infected (n=5) with WT or a 
PbGRASP-KO clone. Beginning on day 3 p.i. until day 6 p.i., blood stage parasitemia was 
measured by Giemsa stained blood smears. Blood Stage: Naïve female Swiss-Webster 
mice were split into two groups of 5 (n=5) and intravenously infected with 0.01% (final 
parasitemia) of  P. berghei parasites or a PbGRASP-KO mutant clone. Starting at day 2 






Figure 11 - Quantification of liver stage parasite burden of PbGRASP-KO by qRT-
PCR  
Three groups of naïve female Swiss Webster (n=5) mice were infected through the tail vein 
with 10,000 sporozoites of WT or  PbGRASP-KO. At 24, 40, or 72-h p.i., mice 
were anesthetized and dissected. Liver samples were placed in TRIzol and homogenized 
to isolate RNA. Complementary DNA (cDNA) was synthesized from the RNA isolates and 
used for qPCR amplification of the 18S ribosomal gene, representing P. 















Figure 12 - Phenotyping the liver stage development of PbGRASP-KO in vitro by IFA 
Two groups of An. stephensi mosquitoes were infected with either WT or a PbGRASP-KO 
clone. Mosquitoes were dissected on day 21 p.i. Three 24 well plates with glass coverslips, 
representing 24, 48, and 67-h p.i., were seeded with 100,000 Hepa1-6 cells for WT and 
PbGRASP-KO infection, in triplicate. 20,000 sporozoites were incubated per well for 3-h 
at 37°C, 5% CO2. At 24, 48, and 67-h p.i., wells were fixed. The cells were imaged through 
fluorescence microscopy, labeled with rabbit anti-TRAP, rat anti-ATG8, mouse anti-





































Figure 13 - Growth of PbGRASP-KO strain in mosquito stage development 
A. On day 17 p.i., A. stephensi mosquitoes infected with WT or PbGRASP-KO were 
dissected and the midguts were isolated and stained to quantify oocysts. There was no 
significant difference in oocyst numbers between WT and PbGRASP-KO Cl 4.  
B. On day 21 p.i., mosquitoes from the same infection groups were dissected and the 
salivary glands were isolated to quantify the average number of sporozoites per female 
mosquito. No significant difference in sporozoite yield of WT and PbGRASP-KO clones 
4 and 16 was observed.  
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Figure 14 - Motility of PbGRASP-KO sporozoite  
Sporozoite gliding ability is observed through fluorescence microscopy. CSP, a sporozoite 
surface protein that facilitates motility, is left behind on the plastic surface during 
sporozoite gliding. CSP trails were fixed and stained with an anti-CSP antibody (green). 













































Figure 15 - Blood stage infection after PbGRASP-KO sporozoite infection 
Two groups of naïve Swiss-Webster mice (n=5) were injected with 10,000 WT or 
PbGRASP-KO sporozoites. Parasitemia in the blood was measured from day 3 to 6 p.i., 
quantified by Giemsa blood smears. Erythrocytic forms of WT and PbGRASP-KO began 
emerging on day 3. Although not statistically significant, fewer PbGRASP-KO parasites 
were quantified than WT 3 days p.i. On day 4, the PbGRASP-KO parasitemia surpassed 
WT. The increased PbGRASP-KO infection was statistically significant on day 5 p.i. (A: 
p=0.018, B: p=0.0004). On day 6 p.i., the PbGRASP-KO parasitemia was significantly 














Figure 16 - Blood stage composition of WT and PbGRASP-KO after sporozoite 
infection 
To inspect blood stage forms of the WT and PbGRASP-KO at day 4 and 5 p.i., Giemsa 
stained blood smears were observed using light microscopy and the diverse blood stages 
were quantified by counting 25 fields per blood smear. (A) Comparative analysis of 
different blood stages on day-4 p.i. (B) Comparative analysis of different blood stages on 
day-5 p.i. Analysis of PbGRASP-KO clone 16 showed a statistically greater number of 
rings compared to WT and fewer trophozoite forms compared to WT at day 4 and 5 p.i. 





















Figure 17 - Quantitative RT-PCR of parasite gene expression in liver stage 
Liver stage parasite burden of PbGRASP-KO (n=5) and WT (n=5) parasite infected Swiss 
Webster mice were quantified by qRT-PCR at 24, 40, 72-h p.i. 18S, a ribosomal gene, was 
selected to measure parasite gene expression in liver samples. Mouse β-actin was selected 
to normalize the parasite 18S expression.  No difference in gene expression between WT 
and PbGRASP-KO was observed at any time point. PCR was done in triplicate for each 
liver sample for each gene. Data represent Mean ± SD. Mann-Whitney statistical test was 



























Figure 18 - Quantitative estimation of liver stage infection by WT and PbGRASP-KO   
A PbGRASP-KO and WT infection of Hepa1-6 cells at 24, 48, and 67-hrs p.i. was observed 
by fluorescence microscopy. Quantification of the exoerythrocytic forms (EEFs) of the 
parasite was obtained by counting parasites identified by HSP70 staining per 50 fields at 













Figure 19 - Volume quantification of EEFs over time  
A PbGRASP-KO and WT infection of Hepa1-6 cells at 24, 48, and 67-hrs p.i. was observed 
by fluorescence microscopy. Volocity software deconvolved images tagged with HSP70 
fluorescence to obtain the average volumic area (volume) of WT and PbGRASP-KO 
(n=35) images at 24, 48, and 67-hrs p.i. At 24-h p.i., the PbGRASP-KO group was 
statistically significant from WT with a larger volume. At 48, 67-hrs. WT and PbGRASP-
































Figure 20 - Size of EEFs at 67-h p.i.  
A PbGRASP-KO and WT infection of Hepa1-6 cells at 67-h p.i. was observed by 
fluorescence microscopy. Images were deconvolved through Volocity Software and 
HSP70 staining was used to obtain the average area (µm2) of the two strains (n³30). The 
difference between WT and PbGRASP-KO area was not significant between the two 




























Figure 21 - Indirect measurement of nucleic acid content of liver forms at 48-h p.i. 
A PbGRASP-KO and WT infection of Hepa1-6 cells at 48-hrs p.i. was observed by 
fluorescence microscopy. Images were deconvolved through Volocity Software and DAPI 
fluorescence overlapping with HSP70 fluorescence was used to obtain the total 
fluorescence intensity of the two strain’s (n=35) nucleic matter at 48-hrs p.i. The difference 
between WT and PbGRASP-KO total DAPI fluorescence intensity was not significant 


























Figure 22 - Morphology of PbGRASP-KO liver forms at 24-h p.i. 
A PbGRASP-KO and WT infection of Hepa1-6 cells at 24-h p.i. is observed by 
fluorescence microscopy. Micronemes (TRAP), the apicoplast/autophagic structures 
(PbATG8), nucleus (DAPI) and cytoplasm (HSP70) show microneme 
compartmentalization in PbGRASP-KO (panels a and b) similar to WT parasites (panel 
c). Panel b depicts clustering of micronemes (TRAP) beneath the parasite plasma 
membrane, (emphasized by arrowheads). Panels d and c show more examples of 
microneme (TRAP) clustering within the cytoplasm of the two strains. PPM, parasite 








































Figure 23 - Morphology of PbGRASP-KO liver forms at 48hour p.i. 
A PbGRASP-KO and WT infection of Hepa1-6 cells at 48-h p.i. observed by fluorescence 
microscopy. Micronemes (TRAP), the apicoplast/autophagic structures (PbATG8), 
nucleus (DAPI) and cytoplasm (HSP70) showing representative examples of a small PV 
(panel a) and a large PV (panel b) for PbGRASP-KO. Panel a illustrates an intense TRAP 
staining beyond the HSP70 signal within the PV space. In panel b, the TRAP staining 
become fainter within the KO, similarly to WT parasites (panel c). Interestingly, the TRAP 
signal was also observed distant from the parasite plasma membrane (emphasized by the 
arrowheads). Panels d and e show more examples of TRAP staining for WT parasites. The 
TRAP signal could correspond to micronemes discarded into the PV, within evaginations 
emanating from the PVM, or expulsion of micronemes beyond the PV, thus in the host 




























Figure 24 -Morphology of PbGRASP-KO liver forms at 67-h p.i. 
A PbGRASP-KO and WT infection of Hepa1-6 cells at 67-h p.i. observed by fluorescence 
microscopy. Micronemes (TRAP), the apicoplast/autophagic structures (PbATG8), 
nucleus (DAPI) and cytoplasm (HSP70) showing representative examples of an 
underdeveloped PV (panel a) and a large PV (panel b) for PbGRASP-KO. The small PV 
in panel a is characterized by a strong residual TRAP staining in the mutant cytoplasm 
while the PV in panel b is similar to the WT PV (panel c). In both strains, ATG8 was re-



































Figure 25 - Ultrastructure of axenic GRASP-deficient P. berghei sporozoites 
EM of 12h-converting sporozoites from WT P. berghei (A) or GRASP-deficient P. berghei 
(B) showing similar features during conversion. In A, panel a illustrates the detachment of 
the inner membrane complex (IMC) from the plasma membrane (PM), allowing the 
overgrowth of the cytoplasm. Double arrows point to areas devoid of submembrane IMC. 
Panel b shows a clustering of micronemes (mi) within a double sac membrane (white 
arrow) magnified in the inset. In B, panels a to c show the remodeling of the IMC in the 
knockout, with progressive dismantling of this organelle from the plasma membrane 
(double arrows) similar to WT parasites. Panel d illustrates the compaction of IMC into 
membrane whorls in the cytoplasm (inset), followed their transport to the plasma 
membrane (panel e) and then expulsion from the parasite (panel f). Panel g shows the 
sequestration of micronemes in a double membrane structure (arrows). m, mitochondrion; 































Figure 26 - Blood stage development of PbGRASP-KO strain 
Two groups of naïve Swiss-Webster mice (n=5) were injected with a final 0.01% WT or 
PbGRASP-KO infected blood. Parasitemia was measured from day 2 to 6 p.i., quantified 
by Giemsa stained thin blood smears.  We observed that PbGRASP-KO clones (4, 13, 16) 

































































Figure 27 - Ultrastructure of GRASP-deficient P. berghei blood forms 
EM of infected red blood cells from mice infected for 5 days with WT P. berghei (A) or 
GRASP-deficient P. berghei (B) showing no difference in the morphology and organellar 
content between the two strains. For the knockout, three infected red blood cells are shown, 
with young stage parasites characterized by large hemoglobin-containing phagosomes (ph) 
(B, panel a); a more advanced parasite stage in which Maurer’s clefts (MC) are formed in 
host cell (hc; B, panel b) similar to WT parasites (A, panel b) and; a later stage 
characterized by a decline in electron-density of the host cytoplasm, indicative of 
hemoglobin consumption by growing parasites (A, panel c). DV, digestive vacuole with 
hemozoin; ER, endoplasmic reticulum; m, mitochondrion; hm, host mitochondrion; n, 








































Reference Primer Sequence 
1.  5’-CCCAAGCTTGGGAGTGTTTATATGGTAAATTTTACATTTACATATC-3’ 
2.  5’-AAAACTGCAGCTATATCCTTAAAAGGAAAATAAATATACGGTGT-3’ 
3.  5’-CGGGGTACCCCGATGAATTGATTGGGGATAAATAAAACTACG-3’ 
4.  5’-GGAATTCCTATATATCCATTTTTCCTCTTCACAAAAGTAATTAC-3’ 
5.  5’-AAGGGAAAGTTATATTTTTTTAGTAACTGGAGT-3’ 
6.  5’-ATGCTTAAGTTTACAATTTAATATTCATACTTTAAGTA-3’ 
7.  5’-GTGCATGCACATGCATGTAAATAG-3’ 
8.  5’-TCACATAATTATATAGTTAGCTAATATTACTCT-3’ 
9.  F: 5’-AAGCATTAAATAAAGCGAATACATCCTTAC-3’ 
10.  R: 5’-GGAGATTGGTTTTGACGTTTATGTG-3’ 
11.  F: 5’-GGCTGTATTCCCCTCCATCG-3’ 
12.  R: 5’-CCAGTTGGTAACAATGCCATGT-3’ 
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